Journal of Neuroinflammation

RESEARCH

Open Access

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns

Luisa Knecht[1,2†], Katrine Dalsbøl[1,2†], Anja Hviid Simonsen[3], Falk Pilchner[4], Jean Alexander Ross[4], Kristian Winge[5], Lisette Salvesen[6], Sara Bech[6], Anne-Mette Hejl[6], Annemette Løkkegaard[6], Steen G Hasselbalch[3,7], Richard Dodel[4], Susana Aznar[1,2], Gunhild Waldemar[3,7], Tomasz Brudek[1,2*] and Jonas Folke[1,2,4*]

Abstract

Background Alzheimer's disease (AD) and Parkinson's disease (PD) are leading neurodegenerative disorders marked by protein aggregation, with AD featuring amyloid-beta (Aβ) and tau proteins, and PD alpha-synuclein (αSyn). Dementia with Lewy bodies (DLB) often presents with a mix of these pathologies. This study explores naturally occurring autoantibodies (nAbs), including Immunoglobulin (Ig)G, IgM, and IgA, which target αSyn, Aβ and tau to maintain homeostasis and were previously found altered in AD and PD patients, among others.

Main text We extended this investigation across AD, PD and DLB patients investigating both the a□nities of IgGs and levels of IgGs, IgMs and IgAs towards αSyn, Aβ and tau utilizing chemiluminescence assays. We con□rmed that AD and PD patients exhibited lower levels of high-a□nity anti-Aβ and anti-αSyn IgGs, respectively, than healthy controls. AD patients also showed diminished levels of high-a□nity anti-αSyn IgGs, while anti-tau IgG a□nities did not di□er signi□cantly across groups. However, DLB patients exhibited increased anti-αSyn IgG but decreased anti-αSyn IgM levels compared to controls and PD patients, with AD patients showing a similar pattern. Interestingly, AD patients had higher anti-Aβ IgG but lower anti-Aβ IgA levels than DLB patients. DLB patients had reduced anti-Aβ IgM levels compared to controls, and anti-tau IgG levels were lower in AD than PD patients, who had reduced anti-tau IgM levels compared to controls. AD patients uniquely showed higher anti-tau IgA levels. Signi□cant correlations were observed between clinical measures and nAbs, with negative correlations between anti-αSyn IgG a□nity and levels in DLB

†Luisa Knecht and Katrine Dalsbøl Shared □rst authorship.

*Correspondence:
Tomasz Brudek
Tomasz.Brudek@regionh.dk
Jonas Folke
Jonas.folke@regionh.dk

Full list of author information is available at the end of the article

patients and a positive correlation with anti-αSyn IgA levels in PD patients. Disease-speci□c changes in nAb levels and a□nity correlations were identi□ed, highlighting altered immune responses.

Conclusion This study reveals distinctive nAb pro□les in AD, DLB, and PD, pinpointing speci□c immune de□ciencies against pathological proteins. These insights into the autoreactive immune system's role in neurodegeneration suggest nAbs as potential markers for vulnerability to protein aggregation, o□ering new avenues for understanding and possibly diagnosing these conditions.

Keywords Alzheimer's disease, Dementia with lewy bodies, Parkinson's disease, Naturally occurring autoantibodies, Alpha-synuclein, Amyloid-beta, Tau

Background

Neurodegenerative diseases are mainly characterized by the pathological accumulation of speci c proteins, which play a pivotal role in disease progression. Alzheimer's disease (AD) is characterized by abnormal accumulation of extracellular amyloid-beta (Aβ) and intracellular tau [1], while Parkinson's disease (PD) is characterized by abnormal intracellular accumulation of alpha-synuclein (αSyn) [2]. Dementia with Lewy bodies (DLB) is characterized by increased Lewy body pathology by disease de nition, but also shares pathologies with both AD, including Aβ plaques and tau neuro brillary tangles, in up to 76% of cases. In contrast, non-dementia PD patients share pathology with AD in fewer cases (7–10%) [3–6]. Although still debated, the consensus emphasizes that the aggregation and toxicity of intermediate toxic seed structures of these pathogenic proteins are considered to be key in disease initiation and progression [7–9].

Naturally occurring autoantibodies (nAbs) are a distinct set of antibodies that recognize self- and non-self-antigens without prior immunization and play a pivotal role in immune clearance of neoepitopes, aggregated and misfolded protein [10]. Although they likely cannot reach the intracellular compartment, they contribute to the engulfment of dying cells and aid in their clearance, while also surveilling the extracellular space, inhibiting the transmission of pathological proteins from cell to cell. ey have been found in large amounts in healthy individuals as well in aberrant levels in patients with neurodegenerative diseases such as AD, PD, DLB, and other neurological disorders (summarized in Table S1) [11]. Previous studies have shown alterations in the levels and a nity of nAbs against αSyn, Aβ, and tau in these diseases, suggesting that dysfunction in the immune clearance of pathological proteins may play an considerable role in the development of neurodegenerative diseases [12, 13]. Generally, there is a consistent pattern observed in the levels and functionality of nAbs in neurodegenerative diseases. Early PD and DLB are characterized by increased levels of anti-αSyn nAbs. On the other hand, AD patients, in general, exhibit reduced levels of anti-Aβ nAbs, while no signi cant di erences are observed in anti-tau nAbs (Table S1). Most studies have predominantly focused on IgG nAbs, under the assumption that immune responses following class-switching are of primary importance. However, signi cant immune functions are also found in the IgM and IgA antibody classes. IgM nAbs, often regarded as the immune system's " rst responders," can rapidly react to alterations in pathological proteins or result in depletion of inhibitors for protein aggregation [14, 15]. IgA's on the other hand play a crucial role in mucosal and gut immunity, which has been implicated as a potential mediator in the pathogenesis of neurodegenerative disorders, such as PD and AD [16, 17]. Furthermore, studies evaluating the functionality of nAbs have revealed important insights. PD patients have been found to have reduced a nity of anti-αSyn autoantibodies in both plasma and cerebrospinal uid (CSF), respectively [18, 19]. is reduction in a nity is also observed in prodromal phases of PD and the atypical parkinsonian disorder multiple system atrophy (MSA) [20]. Similarly, AD patients exhibit reduced a nity for anti-Aβ nAbs [21]. e precise role of nAbs in neurodegenerative disorders, however, remains a subject of ongoing debate and whether these di erences in levels, speci city, and e cacy between healthy individuals and those with PD, AD or DLB, suggest that they may contribute to disease onset or progression. However, promising results have been obtained in preclinical animal models, where nAbs have been evaluated in terms of passive immunization (reviewed by [22]). More recently, positive results have been reported in clinical trials for AD using donanemab and lecanemab, both of which target Aβ structures [23, 24].

Here, we evaluated the repertoire of high a nity Immunoglobulin (Ig)G nAbs speci c to αSyn, Aβ, and tau in AD, PD, and DLB patients compared to healthy controls. We also investigated the levels of nAbs of different classes (Immunoglobulin (Ig)G, IgM, and IgA). Understanding the connection between nAbs and protein pathology could provide valuable insight into disease mechanisms and identify potential targets for therapeutic treatment.

Materials and methods

Demographics

A total of 235 plasma samples were collected from three di erent biobanks for this study (Table 1 and 2). (1) e samples included 38 PD and 15 DLB patients samples, and 29 control samples from the Bispebjerg Movement Disorder Biobank (BMDB) at the Department of Neurology, Bispebjerg-Frederiksberg Hospital, Copenhagen University Hospital, Denmark (2) 69 AD and 31 DLB patient samples were obtained from the Danish Dementia BioBank (DDBB), Rigshospitalet, Copenhagen University Hospital, Denmark, and (3) 12 PD patients and 41 controls from the research-biobank at the Centre for Neuroscience and Stereology, Bispebjerg-Frederiksberg Hospital, Copenhagen University Hospital, Denmark. Only cases that met the international criteria for probable disease were included in the study [25–28]. e healthy control individuals had no central nervous system conditions, immunological disorders, or ongoing immunomodulatory treatment. All participants provided written consent for inclusion in the biobanks, adhering to the World Medical Association Declaration of Helsinki.

αSyn/Aβ/tau competition electrochemiluminescence immunoassay (ECLIA)

e a nity of anti-αSyn/Aβ/tau nAbs was assessed based on a competitive antigen-antibody reaction, whereby increasing antigen concentrations in the uid phase facilitated distinguishable repertoires of high-a nity and low-a nity antibody fractions, previously developed in-house [18]. In this study the assay was adapted and optimized for Aβ and tau. In brief, 96-well mesoscale discovery (MSD) plates were coated overnight at 4 °C with antigens (αSyn: 20 ng/mL (rPeptide, #S-1001), standard small spot MSD plate (MSD, #L45XA); $Aβ_{1-42}$: 1 µg/mL (rPeptide, #A-1002), standard small spot MSD plate (MSD, #L45XA); tau: 1 ng/mL (rPeptide, #T-1001), high bind plate (MSD, #L15XB)) in ice-cold 0.1 M carbonate bu er, pH 8.5 (Sigma–Aldrich, #C3041). Next, the plates were blocked for 1 h at 800 rpm (αSyn: PBS+BSA 3% (Sigma–Aldrich, #05482); Aβ: Intercept™ Blocking Buffer in PBS (LI-COR, #927-90001); tau: ROTI®Block1X (Carl Roth, #A151). Meanwhile, plasma samples were diluted (αSyn: 1:200; Aβ/tau: 1:100) in PBS+BSA-0.1% (Sigma–Aldrich, #05482) and preincubated with the antigen (αSyn: 1000 nM/2 nM/0.2 nM, 0 nM; Aβ: 600 nM/6 nM/0.06 nM/0.0006 nM/0 nM; tau: 100 nM/1 nM/0.01 nM/0 nM) for 1 h before adding onto a newly washed antigen-coated plate (5 times with PBS+0.05%-Tween-20 (Sigma–Aldrich, #P7949)) and incubated for 1 h at 800 rpm. After an additional washing step (5 times with PBS+0.05%-Tween-20 (Sigma–Aldrich, #P7949)), SULFO-tag goat anti-human (1:10,000; MSD, #R32AJ-1) in PBS+BSA-0.1% (Sigma–Aldrich, #05482) was added and eventually incubated for 1 h at 800 rpm. Finally, the plate was washed (5 times with PBS+0.05%-Tween-20) and Read Bu er T (1:2 (MSD, #R92TC)) was added upon reading the plate immediately before the MSD Sector Imager/QuickPlex SQ 120 Reader (MSD, LLC, USA). e percentage of max binding for each sample and pool was calculated as follows:

$$\%\ of\ max\ binding = \frac{(ECLIA_{sample\ OD} - ECLIA_{OD\ at\ 1000\ nM\ competitor\ (0\%\ binding)})}{ECLIA_{OD\ at\ 0\ nM\ competitor\ (100\%\ binding)}} \times 100$$

.IgG, IgM and IgA anti-αSyn/Aβ/tau measurements

Total levels of anti-αSyn/Aβ/tau nAbs were measured by indirect ELISA as previously described [19, 20, 29] with few adjustments. In brief, 96-well polystyrene microtiter plates (Nunc MaxiSorp® at-bottom) were coated overnight with antigens (αSyn: 5 µg/mL (rPeptide, #S-1001-2); Aβ1–42: 5 µg/mL (rPeptide, A-1002); tau: 0.5 µg/mL (rPeptide, T-1001)) in ice-cold 0.1 M carbonate bu er, pH 8.5 (Sigma–Aldrich, #C3041). e plates were then emptied and blocked for 2 h at RT with PBS+BSA-3% (Sigma–Aldrich, #05482)+Tergitol-0.1% (Sigma–Aldrich #NP40S). Following a subsequent washing cycle of 5 times with PBS+0.05%-Tween-20 (Sigma–Aldrich, #P7949), plasma samples were diluted (1:50 for anti-αSyn/Aβ/tau IgA and 1:100 for anti-αSyn/Aβ/tau IgG/IgM) in dilution bu er (PBS+0.1%BSA+0.05% + Tween-20) and incubated for 1 h at RT. After another washing cycle (5 times with PBS+0.05%-Tween-20), secondary HRP-conjugated anti-Ig antibodies (anti-IgG

Table 1 Demographic and clinical data

	AD (*N*=69)	PD (*N*=50)	DLB (*N*=46)	NC (*N*=70)	*p* values
Age [years]	70.4 (8.1) [51–89]	68.4 (7.4) [52–84]	72.8 (6.4) [56–88]	71.4 (9.1) [52–90]	*0.020**
Sex (M/F)	35/34	24/26	33/13	31/39	*0.027***
Age at onset [years]	68.0 (8.6) [48–88]; 81%	61.4 (8.3) [44–78]	69.6 (8.8) [38–87]; 98%	-	0.267#
MMSE	24.1 (3.9) [12–30]	-	25.8 (4.0) [16–30]; 67%	-	*0.016#*
H&Y	-	2.3 (0.9) [1–5]; 72%	2.4 (0.9) [1–3]; 32%	-	0.461#
Disease Duration [years]	2.2 (1.2) [0.5-5]; 81%	7.0 (4.1) [0–15]	3.2 (3.3) [0–21]; 98%	-	*<0.001%*
Biobank	DDBB	BMDB; CNS-lab	DDBB; BMDB	BMDB; CNS-lab	

*: Welch ANOVA. **: chi-squared test. #: Mann–Whitney test. %: Kruskal-wallis test. MMSE: Mini Mental State Examination (MMSE); H&Y: Hoehn & Yahr (7-scale); M: Male; F: Female; DDBB: Danish Dementia BioBank; BMDB: Bispebjerg Movement Disorder Biobank; CNS-lab: Centre for Neuroscience and Stereology. $: PD vs. DLB (collectively), $p<0.05$

Table 2 Statistical comparison of nAb a□nities and levels for αSyn, Aβ and tau

Antigen	**Model statistics**			**Groups**	**Sex**	**Age**	**DLB-AD**	**PD-AD**	**NC-AD**	**PD-DLB**	**NC-DLB**	**NC-PD**
αSyn	*p value*	R^2	*F-stat*	*p value*	*p value*	*p value*	*p value for multiple comparison**					
2 nM	0.116	0.024	F(5;161) = 1.80	0.053	0.296	0.976						
0.2 nM	*0.033*	0.047	F(5;147) = 2.51	*0.016*	0.317	0.120	0.321	0.997	*0.037*	0.305	0.879	*0.045*
IgG	*1.9E-07*	0.150	F(5;211) = 8.62	*1.2E-07*	0.430	0.686	*0.003*	0.472	*0.023*	*< 0.001*	*< 0.001*	0.640
IgM	*6.1E-07*	0.139	F(5;213) = 8.01	*5.8E-07*	0.286	0.260	0.998	*0.007*	*< 0.001*	*0.045*	*< 0.001*	0.419
IgA	0.334	0.004	F(5;207) = 1.15	0.225	0.168	0.588						
Aβ	*p value*	R^2	*F-stat*	*p value*	*p value*	*p value*	*p value for multiple comparison**					
0.6 nM	0.033	0.040	F(5,177) = 2.49	*0.022*	0.450	0.225	0.938	0.098	*0.031*	0.465	0.297	0.998
0.06 nM	0.089	0.025	F(5,177) = 1.95	0.068	0.337	0.915						
IgG	*0.038*	0.030	F(5,224) = 2.41	*0.035*	0.318	0.167	0.640	0.130	*0.032*	0.856	0.637	0.984
IgM	*0.020*	0.037	F(5,222) = 2.76	*0.026*	0.174	0.456	0.616	0.999	0.215	0.686	*0.020*	0.243
IgA	*0.049*	0.026	F(5,227) = 2.26	*0.015*	0.770	0.456	*0.011*	0.333	0.125	0.470	0.611	0.985
Tau	*p value*	R^2	*F-stat*	*p value*	*p value*	*p value*	*p value for multiple comparison**					
1 nM	0.817	0.015	F(5,180) = 0.45	0.937	0.267	0.587						
0.1 nM	0.109	0.023	F(5,174) = 1.83	0.082	0.155	0.916						
IgG	*0.033*	0.031	F(5,226) = 2.47	*0.010*	0.533	0.756	0.264	*0.005*	0.213	0.598	0.999	0.389
IgM	*0.020*	0.036	F(5,227) = 2.74	*0.036*	0.057	0.575	0.977	0.091	0.955	0.335	0.826	*0.027*
IgA	0.557	0.005	F(5,225) = 0.79	0.871	0.078	0.891						

*: Multiple comparison modulated for covariables (sex and age)

(1:20,000; Abcam, #ab98624), biotin-conjugated anti-IgM (1:5,000; Sigma–Aldrich, #B1265), and anti-IgA (1:1,000 for αSyn/Aβ; 1:2000 for tau; ermo Fisher Scienti c, #PA1-74395) were diluted in dilution bu er, added to the plates and incubated for 2 h at RT. An additional step was carried out for the biotin-conjugated IgM antibody, with streptavidin–peroxidase (1:10,000; Sigma–Aldrich, #S5512) for 30 min at RT. Next, the plates were washed once again (5 times with PBS + 0.05%-Tween-20), and tetramethylbenzidine (TMB) Liquid Peroxidase Substrate (Sigma–Aldrich, #T8665) was added for 30 min in the dark at RT prior to reaction termination by the addition of 0.5 N sulfuric acid (Sigma–Aldrich, #319570). Finally, the absorbance was measured at 450 nm and 620 nm on a MultiSkan™ FC Microplate Reader (ermo Fisher Scienti c, USA). All data were normalized to positive controls on each individual plate. Positive controls consisted of pooled plasma samples, from controls and patients, added to each plate to account for plate-to-plate variability.

Statistical analyses

For demographic group comparison, we applied Welch ANOVA followed by the Games-Howell test for multiple comparisons for age since the data was normally distributed but has di erence in variances, the chi-squared test for sex, the Mann–Whitney U test for age at onset, MMSE, Hoehn & Yahr and disease duration. Outliers were removed from analyses using ROUT with false discovery rate (FDR), Q = 1%. Normality was assessed using the D'Agostino Omnibus test. For group comparison, we applied multiple linear regression modeling including covariates age and sex, since small discrepancies between groups were observed, using *ANOVA* from the *car* package [30]. For multiple comparisons, the *glht* and *mcp* functions from the *multicomp* package [31] were applied using Tukey's range test. Correlations between measured outcomes and clinical data were assessed using Spearman's rank-order correlation. Spearman's correlation matrices were constructed using *corrplot* package [32]. Data were analyzed using R v. 3.5.2 [33] and GraphPad Prism 9.4.1 (GraphPad Software Inc., USA).

Results

Anti-αSyn/Aβ/tau high-a□nity nAbs in AD, DLB and PD patients

To assess the functionality of nAbs and their capacity to form stable immunocomplexes across various diseases, we analyzed the binding a nity of anti-αSyn, -Aβ, and -tau IgG nAbs in patients with AD, DLB and PD, as well in control individuals. To perform these analyses, we utilized our well-characterized competition assay with minor adjustments [19, 20, 34]. Based on initial competition curves obtained from a subset of 10 randomly selected age- and sex-matched patients and control individuals (Fig. 1A, D and G), we chose two di erent conditions to rmly evaluate the high-a nity nAb repertoire.

e analysis of individual samples revealed notable differences in the high-a nity repertoire of anti-αSyn and anti-Aβ IgG nAbs. When exposed to 0.2 nM free αSyn, PD patients ($p = 0.045$) and AD patients ($p = 0.037$) (Fig. 1B; Table 3) exhibited a signi cantly reduced repertoire of high-a nity anti-αSyn IgG compared to controls. Additionally, when exposed to 0.6 nM free Aβ, AD patients only demonstrated signi cantly lower amounts of high-a nity anti-Aβ IgG compared to controls. No di erences in tau a nity reactivity were observed between groups.

Anti-αSyn/Aβ/tau IgG, IgM and IgA nAbs in AD, DLB and PD patients

To explore the reactivity of di erent antibody classes in the immune system, namely, IgG, IgM, and IgA, toward αSyn, Aβ, and tau in patients with AD, DLB, PD, and controls, we conducted indirect ELISA analyses. Exploring the repertoires of anti-αSyn IgG, IgM, and IgA nAbs, we observed that AD and DLB patients exhibited signi cantly higher levels of anti-αSyn IgG than controls (AD: $p = 0.023$; DLB: $p < 0.001$) (Fig. 2A; Table 3). More signi cantly, DLB patients exhibited increased levels of anti-αSyn IgG compared to both AD ($p = 0.003$) and PD patients ($p < 0.001$) (Fig. 2A; Table 3). In terms of anti-αSyn IgM, both AD and DLB patients demonstrated reduced levels compared to PD (AD: $p = 0.007$; DLB: $p = 0.045$) and controls (AD: p



Fig. 2 Relative anti-αSyn (**A-C**), -Aβ (**D-F**) and -tau (**G-I**) IgG, IgM and IgA nAb levels in AD, DLB and PD patients as well as controls. Data are presented as normalized optical (normalized to positive controls on each individual plate) densities in truncated violin plots with median (horizontal line). Group comparisons were performed by applying multiple linear regression models including covariates age and sex and post hoc multiple comparison testing using Tukey's range test. Statistically signi□cant p-values (< 0.5) are depicted

in Fig. 3A and Table S3. is was with the exception of the anti-Aβ IgG versus anti-tau IgM relationship (r=0.230, p=0.059). Notably, strong correlations persisted across all four examined groups (AD, DLB, PD and controls) for the anti-tau IgA, IgG, IgM and the anti-Aβ IgA, IgG, IgM (Fig. 3A-D, Table S1-4), respectively. Furthermore, a positive correlation was found between anti-Aβ IgM and IgG (r=0.284, p=0.019), and similarly between anti-αSyn IgM and IgG (r=0.525, p=1.2E-05). A positive correlation was also observed between the a nity of anti-tau IgG for two concentrations of free tau (r=0.466, p=4.3E-04). Interestingly, in controls, no correlation was between the two a nity measures for anti-Aβ IgGs (r=-0.082, p=0.601), contrasting with the positive correlations observed in AD (r=0.693, p=1.2E-08), DLB (r=0.456, p=0.009) and PD (r=0.567, p=1.7E-04) patients.



Fig. 3 Spearman's correlation matrix of the anti-αSyn/Aβ/tau a□nities and IgGs, IgMs and IgAs levels. Aβ: amyloid-beta, Ig: immunoglobulin, αSyn: alpha-synuclein. Scalebar ranging from Spearman's *r* = -1 (*red*, negative correlation) to + 1 (*blue*, positive correlation). Only signi□cant correlations are showed. P-values < 0.05 were considered signi□cant

In AD patients, while many correlations remained (Fig. 3B, Table S4), there were ve exceptions, in addition to the previously described Aβ high-a nity correlation. ese exceptions included four positive correlations: between high-a nity anti-αSyn 0.2 nM and anti-αSyn 2 nM (r=0.492, p=4.4E-04), anti-αSyn IgA and anti-Aβ IgM (r=0.289, p=0.024), high a nity anti-tau 0.1 nM and anti-tau 1 nM (r=0.835, p=3.2E-13) and anti-tau IgG versus anti-tau IgM (r=0.259, p=0.034). Additionally, a negative correlation was noted between anti-Aβ IgM and high-a nity anti-Aβ IgGs (r=-0.285, p=0.047).

In case of DLB patients compared to healthy controls, eight positive correlations associated with anti-αSyn IgA, IgG, and IgM versus anti-Aβ, and anti-tau IgG, and IgM

were eliminated (Fig. 3C, Table S5). Moreover, anti-αSyn IgA and IgG showed negative correlations with high-a nity anti-Aβ IgG (r=-0.462, p=0.012) and high-a nity anti-αSyn IgG (r=-0.430, p=0.018), respectively. Additionally, the anti-αSyn IgG and anti-αSyn IgM interrelationship was ablated (r=-0.117, p=0.497).

In PD patients, compared to healthy controls, there was a notable impact on the correlations involving anti-αSyn and anti-tau IgGs (Fig. 3D, Table S6). Speci cally, anti-αSyn IgG exhibited a negative correlation with high-a nity anti-Aβ IgGs (r=-0.418, p=0.013), diverging from the previously observed positive correlations with anti-Aβ IgG, anti-tau IgG and IgM in controls, which were no longer present. Furthermore, anti-αSyn IgA was found to be negatively correlated with high-a nity anti-αSyn IgGs (r=-0.403, p=0.020). Positive interrelationships were observed between anti-tau IgG and high-a nity anti-Aβ IgGs (r=0.460, p=0.004), anti-tau IgM and anti-Aβ IgGs (r=0.369, p=0.008), and between anti-αSyn IgM and high-a nity anti-αSyn IgGs (r=0.394, p=0.023).

Discussion

In the explorations of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), the role of immune clearance has emerged as a topic of signi cant interest. is stems from the historical precedent set by the discovery of nAbs against the Aβ protein in AD as early as 2001 [35]. However, even with decades of research, the exact function, and implications of these nAbs remain a subject of debate. Our study o ers a fresh perspective by examining the binding a nity of nAbs to essential proteins associated with AD, DLB and PD patients.

By employing our well-characterized competition assay [18–20, 34], we analyzed the high-a nity repertoire of nAbs against αSyn, Aβ, and tau in AD, DLB and PD patients, as well as healthy control subjects. We extended our prior ndings in PD to include AD, demonstrating signi cantly reduced high-a nity anti-αSyn IgG nAbs compared to controls, and further demonstrating reduced high-a nity Aβ nAbs in AD compared to controls. Although the common paradigm separates αSyn pathology into PD and Aβ pathology into AD, the broader landscape of neurodegenerative disorders reveals that between 20 and 40% of all AD cases show pathological αSyn accumulation in the brain [36, 37]. In addition to co-occurrence in pathology, several mechanisms have been proposed for the role of αSyn involvement in AD. αSyn interacts with Aβ and tau, promoting their aggregation and toxicity and contributing to the complexity and severity of neurodegenerative processes [38]. It is likely a key e ector in neurotransmitter release and synaptic function, which have been shown to be compromised in AD [39]. Additionally, emerging evidence suggests that αSyn acts as a culprit in neuroin ammatory processes and contributes to activating microglia, as observed both in PD and potentially AD [40, 41]. Although these potential links are intriguing, we can only speculate which processes are present in this study's AD patients and whether they have αSyn co-pathology, which could explain their reduced functionality of anti-αSyn nAbs.

Earlier research has emphasized the ability of IgG nAbs to regulate in ammation and to facilitate the clearance of neurotoxic aggregates [42]. e presence of disease-speci c IgG nAbs targeting pathological proteins such as αSyn, Aβ and tau suggests an intricate interplay between the immune system and the pathogenesis of neurodegenerative disorders [11, 43]. Although the intracellular location of αSyn and tau aggregates makes it unlikely that nAbs penetrate the cell membrane and clear the aggregates intracellularly, they are more likely to scavenge the extracellular space, clearing material transmitting between cells and aiding in the degradation of cellular material after apoptosis. Considering that nAbs play a crucial role in regulating immune clearance mechanisms, any abnormalities in the nAb pro le could potentially exacerbate the pathogenesis of neurological conditions. is observation was recently established by the success of two di erent passive immunization strategies in treating AD. e e ectiveness of lecanemab and donanemab in AD patients [23, 24] manifests the importance of functional regulation of key pathological proteins. Passive immunization seems to have the potential to bolster compromised immune system functions in neurodegenerative diseases. To date, no conclusive study of passive immunization in PD patients has proven successful. However, promising secondary outcomes were recently achieved in the AMULET study, a Phase II passive immunization trial in MSA patients. is trial was based on the hypothesis that the treatment would not clear existing aggregates but would instead slow down or halt the spread and seeding of aSyn to other cells [44]. ese results, taken together with the lacanemab and donanemab trials in AD, further imply that intravenously administrated antibodies can partially reach the brain, consistent with previous ndings showing di erences in nAbs in CSF samples from PD and AD, which also correlate with plasma levels [19, 35, 45–48]. Several factors, including the absence of precise antibody candidates, de ned pathological hallmarks, and challenges in enrolling patients with varying disease durations or early in the disease onset into the trials, could contribute to this lack of success. Furthermore, the fact that the main pathological processes are di erent would be the most obvious reason. is contrast may suggest distinct nAb-associated disease mechanisms or pathological responses between AD and PD. Con rming this, recent studies o er seemingly paradoxical perspectives on the role of

B cells in disease pathogenesis. For instance, Scott et al. [49]. posited that B cells play a protective role in a PD model, whereas a 2021 study hinted at their pathological role in an AD model [50].

Plasma IgM levels were altered in AD, DLB and PD patients. Interestingly, we observed that AD and DLB patients had reduced anti-αSyn IgM titers compared to PD patients and controls. DLB patients also presented reduced anti-Aβ IgM titers. IgM nAbs bind to disease-speci c proteins and in uence the aggregation of these proteins [42, 51]. e pentameric structure of IgM endows it with multivalency, allowing it to bind to multiple copies of proteins, such as αSyn, Aβ and tau [52, 53].

is property could facilitate more e cient clearance. IgM's relatively unspeci c yet rapid immune response makes it an essential component of the innate immune system. In neurodegenerative diseases, this could mean that IgM acts as an early responder to neural in ammation or protein aggregation, is secreted quickly, and plays a role in complement activation. Harvesting these properties has been proposed as a passive immunization strategy, with the scFv-Fc format allowing for multimerization into pentameric structures, improving the binding and functionality of the antibodies [54]. On the other hand, reduced antigen-speci c IgM nAbs have been observed leading to increased IgG nAbs towards self-antigens [55], possibly explaining the subsequent increased anti-aSyn IgG nAbs in AD and DLB. Further understanding the multifaceted roles of IgM in AD, DLB and PD could o er novel insights into neurodegenerative disease pathogenesis and explore its potential as a therapeutic approach.

Finally, this study is the rst to explore the relevance of pathology-related IgA compartments in neurodegenerative diseases. Our data suggest a positive correlation between the Hoehn and Yahr (H & Y) scale and anti-αSyn IgA nAbs in individual plasma samples from PD patients (Fig. S1D). IgAs are primarily known for their role in mucosal immunity, such as lining the gastrointestinal tract, as well as other openings inside the nose and mouth [56]. In addition to their localization at mucosal sites, IgAs are also found in the circulatory system [56]. One of their critical functions is to maintain harmonious homeostasis between the microbiota and the host's immune response [57]. e role of the gut-brain axis, especially in PD, has attracted increasing interest. One intriguing observation is the identi cation of αSyn pathology at the gut's mucosal lining in PD patients [58, 59]. Furthermore, speci c infections such as *Helicobacter pylori* have been implicated in PD [60], and urinary tract infections have been associated with the atypical parkinsonian disorder, MSA [61], possibly triggering αSyn misfolding, which can spread to the brain via the vagus nerve [62, 63]. Speci cally, related to IgA in the context of the gut-brain axis, recent studies found that the IgA to IgM/IgD ratio was nearly 2-fold increased in PD patients [64]. Moreover, IgA-producing plasma cells are not only present in the meningeal venous sinuses but also associated with increases during aging and after an intestinal barrier breach [65]. B-cell receptor sequencing further identi ed these cells as originating from the intestine [65]. In the realm of AD, recent research has reported elevated IgA levels in the plasma and brain tissue of APOE-ε4 non-carriers, establishing intracerebral transfer of IgA's [17].

ese and our discoveries indicate a possible connection between gut-speci c IgA responses, healthy aging and the onset or progression of PD and related neurodegenerative conditions.

As neurodegenerative pathologies progress and redistribute, distinct changes in nAb function and concentration emerge, with variability across diseases. In AD, Aβ pathology accumulates prior to tau pathology [66], and both occur before clinical symptoms manifest. is sequence implies that nAb-response dynamics may differ between Aβ and tau. Similarly, in PD and DLB, αSyn accumulation is an early event, possibly starting many years prior to disease onset [67, 68], which may explain the heightened anti-αSyn response observed in early and prodromal PD stages [20, 45] and in idiopathic REM sleep behavior disorder (iRBD) patients [49].

e precise interactions among nAb a nity, disease pathology, and immune regulation remain complex and incompletely understood. However, di erential responses in nAbs targeting key neurodegenerative proteins suggest intricate interplay between nAb a nity and disease processes. One of the most striking observations is the lack of correlation between the a nity of anti-Aβ IgGs in controls (Fig. 3A) and the strong positive correlations in AD and PD patients (Fig. 3B and D). One hypothesis posits that nAb-producing B cells is pre-existing and slight antigenic pushes, drives generation of IgGs and IgAs by di erentiating into plasma cells. is process enables hypermutation and class-switching, as suggested by Reynefeld et al. 2020 [69]. e further persistence of IgG and IgM correlations, particular in controls, suggest that these nAbs may serve protective and regulatory roles, which become disrupted in disease. e reduction in these correlations in patients implies an overall breakdown in the immune system's ability to coordinate the recognition and removal of misfolded proteins. On the other hand, the disruptions could merely be driven by the chronic presence of Aβ plaques and increased Aβ1–42 levels in the brains of AD patients and αSyn Lewy body aggregates in PD patients, or both in DLB patients and that these high-a nity nAbs are sequestered in the brain, which could contribute to their lower levels in peripheral circulation. However, the non-changes in relation to tau and the absence of correlation between a nity and disease duration, cognitive impairment and motor

disability talks against it. Only in DLB patient, a signi - cant decrease was observed in relation to anti-αSyn IgG a nity and levels, suggesting that both a nity and levels are decreased during disease progression (Table S2), suggesting a link between development of αSyn accumulation and anti-αSyn nAbs. is needs to be explored further, in brain and body, and although, we can only speculate at this stage, the breakdown of interrelationships between di erent nAbs across disease groups support the theory that chronic neuroin ammation and immune dysregulation are shared features across neurodegenerative diseases.

e present study, while insightful, has several limitations. First, its cross-sectional design captures antibody dynamics at a single time point, limiting understanding of their progression over time. Longitudinal studies are needed to clarify these changes, potentially in the prodromal stages. Second, peripheral blood measurements may not fully re ect central nervous system (CNS) pathology, as blood-brain barrier integrity and antibody sequestration in the brain were not directly assessed. e study also focuses on Aβ, tau, and αSyn autoantibodies, potentially overlooking other disease-relevant proteins.

e mechanisms behind the observed antibody variations, particularly the role of nAbs in disease progression, remain speculative. Finally, the study did not explore other immune pathways or antibody subclasses that may play critical roles in neurodegeneration. Future research addressing these limitations is necessary for deeper mechanistic understanding.

Conclusions

e multifaceted nature of neurodegenerative diseases is re ected in the aberrant levels of nAbs and their classes. While the utility of nAbs as diagnostic biomarkers remains a subject of ongoing debate, we argue that their inherent variability among groups and individuals limits their e ectiveness in this role. However, their importance in elucidating disease mechanisms should not be underestimated, and they may prove valuable in identifying subgroups within the disease spectrum. Our study provides evidence of a dysfunctional immune system in neurodegenerative diseases, suspected to impair the endogenous clearing mechanism of pathological proteins, namely Aβ, αSyn and tau. is suggests a relationship between disease-speci c immunoglobulins and pathogenesis, although the speci c nature of this relationship has yet to be clearly de ned.

Abbreviations

AD	Alzheimer's disease
Aβ	Amyloid-beta
PD	Parkinson's disease
aSyn	Alpha-synuclein
DLB	Dementia with Lewy bodies
nAbs	Naturally occurring autoantibodies
Ig	Immunoglobulin
MSA	Multiple system atrophy
CSF	Cerebrospinal uid
PDD	Parkinson's disease dementia
VaD	Vascular dementia
FTD	Frontotemporal dementia
MSA	Multiple system atrophy
PSP	Progressive supranuclear palsy
LRKK2	Leucine-rich repeat kinase 2
bvFTD	Behavior-variant FTD
SCA	Spinocerebellar ataxia
sAD	suspected AD
ADRD	AD-related dementia
NDs	Neurodegenerative disorders
NPH	Normal pressure hydrocephalus
RBD	REM-sleep behavior disorder
ApoE	Apolipoprotein E
E4	Epsilon 4
MCI	Mild cognitive impairment
OND	Other neurological diseases
IC	In ammatory controls
ALS	Amyotrophic lateral sclerosis
CJD	Creutzfeld-Jakob disease
CBD	Corticobasal degeneration
WE	Wernicke encephalopathy
BMDB	Bispebjerg Movement Disorder Biobank
DDBB	Danish Dementia BioBank
CNS-lab	Centre for Neuroscience and Stereology
ECLIA	Electrochemiluminescence immunoassay
MSD	Mesoscale Discovery
PBS	Phosphate Bu ered Saline
BSA	Bovine Serum Albumin
ELISA	Enzyme-linked Immunosorbent assay
TMB	3,3', 5,5 tetramethylbenzidine dihydrochloride
FDR	False Discovery Rater
nM	Nanomolar
H&Y	Hoehn & Yahr staging (7-stage)
NC	Non-neurological controls

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12974-024-03293-3.

Supplementary Material 1

Acknowledgements

We would like to express our gratitude to the Bispebjerg Movement Disorder Biobank (BMDB) at the Department of Neurology, Bispebjerg-Frederiksberg Hospital, Copenhagen University Hospital, Denmark and the Danish Dementia BioBank (DDBB), Rigshospitalet, Copenhagen University Hospital, Denmark, for generously donating patient samples for the study.

Author contributions

LK and KD contributed equally to this work and conducted the majority of experiments and analyzed data and authored the manuscript. AHS, KW, LS, SB, A-MH, AL, SGH, GW contributed to patient material and clinical assessments. FP, JAR, RD and SA: contributed by allocating resources, and interpreting data. TB: contributed to the design, conception and execution of experiments and interpreted data. JF: secured funding, contributed to conception, design and execution of experiments, interpreted data and authored the manuscript. All authors reviewed and revised the manuscript.

Funding

This work was supported by the Danish Independent Research Fund, DFF (grant nr.: 0129-00015B), the Danish Parkinson Foundation (grant nr.: A457), Toyota-Fonden and Tømmerhandler Vilhelm Bangs Fond.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval

This project was approved by the Danish National Committee on Health Research Ethics, Copenhagen Regional Area (j.no.: H-15016232) and the Danish Data Protection Agency (j.no.: P-2020-937). All participants gave written consent for inclusion in the biobanks according to the World Medical Association Declaration of Helsinki.

Competing interests

The authors declare no competing interests.

Author details

[1]Centre for Neuroscience and Stereology, Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 6B, Entrance 11B, 2. oor, Copenhagen, NV DK-2400, Denmark
[2]Copenhagen Center for Translational Research, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 4B, Copenhagen, NV DK-2400, Denmark
[3]Danish Dementia Research Centre, Copenhagen University Hospital - Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen Ø DK-2100, Denmark
[4]Chair of Geriatric Medicine, Center for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, Hufelandstraße 55, DE-45147 Essen, Germany
[5]Odense University Hospital, University of Southern Denmark, Copenhagen, Denmark
[6]Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 7, Copenhagen, NV DK-2400, Denmark
[7]Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen Ø DK-2100, Denmark

Received: 18 September 2024 / Accepted: 11 November 2024
Published online: 03 December 2024

References

1. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14:32. https://doi.org/10.1186/s13024-019-0333-5.
2. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R. Goedert, α-Synuclein in Lewy bodies. Nature. 1997;388:839–40. https://doi.org/10.1038/42166.
3. Hepp DH, Vergoossen DLE, Huisman E, Lemstra AW, Bank NB, Berendse HW, Rozemuller AJ, Foncke EMJ, Van De Berg WDJ. Distribution and load of amyloid-b pathology in Parkinson disease and dementia with lewy bodies. J Neuropathol Exp Neurol. 2016;75:936–45. https://doi.org/10.1093/jnen/nlw070.
4. Jellinger KA, Corey-Bloom J, Merdes AR, Hansen LA. In uence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies [3] (multiple letters). Neurology. 2004;62:160. https://doi.org/10.1212/WNL.62.1.160.
5. Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T, Katsuse O, Uchikado H, Aoki N, Kosaka K, Arai H, Sato K. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett. 2010;486:19–23. https://doi.org/10.1016/j.neulet.2010.09.036.
6. Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor J-P, Thomas A, Attems J, McKeith I. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:5. https://doi.org/10.1186/s13024-019-0306-8.
7. Golde TE, Miller VM. Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther. 2009;1:5. https://doi.org/10.1186/alzrt5.
8. Hartl FU. Protein Misfolding Dis Annu Rev Biochem. 2017;86:21–6. https://doi.org/10.1146/annurev-biochem-061516-044518.
9. Sami N, Rahman S, Kumar V, Zaidi S, Islam A, Ali S, Ahmad F, Hassan MI. Protein aggregation, misfolding and consequential human neurodegenerative diseases. Int J Neurosci. 2017;127:1047–57. https://doi.org/10.1080/00207454.2017.1286339.
10. Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol. 2009;30:43–51. https://doi.org/10.1016/j.it.2008.10.002.
11. Wu J, Li L. Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res. 2016;30:361–72. https://doi.org/10.7555/JBR.30.20150131.
12. Ciccocioppo F, Bologna G, Ercolino E, Pierdomenico L, Simeone P, Lanuti P, Pieragostino D, Del Boccio P, Marchisio M, Miscia S. Neurodegenerative diseases as proteinopathies-driven immune disorders. Neural Regen Res. 2020;15:850–6. https://doi.org/10.4103/1673-5374.268971.
13. Deleidi M, Maetzler W. Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders., Int. J. Alzheimers. Dis. 2012 (2012) 391438. https://doi.org/10.1155/2012/391438
14. Papuć E, Rejdak K. Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonism. J Neural Transm. 2017;124:209–16. https://doi.org/10.1007/s00702-016-1632-4.
15. Agrawal S, Abud EM, Snigdha S, Agrawal A. IgM response against amyloid-beta in aging: a potential peripheral protective mechanism. Alzheimers Res Ther. 2018;10:81. https://doi.org/10.1186/s13195-018-0412-9.
16. Brown EL, Essigmann HT, Ho man KL, Alexander AS, Newmark M, Jiang Z-D, Suescun J, Schiess MC, Hanis CL, DuPont HL. IgA-Biome pro les correlate with clinical Parkinson's Disease subtypes. J Parkinsons Dis. 2023;13:501–13. https://doi.org/10.3233/JPD-230066.
17. Pocevičiūtė D, Nuñez-Diaz C, Roth B, Janelidze S, Giannisis A, Hansson O, Wennström M, Bank TNB. Increased plasma and brain immunoglobulin A in Alzheimer's disease is lost in apolipoprotein E ε4 carriers. Alzheimers Res Ther. 2022;14:117. https://doi.org/10.1186/s13195-022-01062-z.
18. Brudek T, Winge K, Folke J, Christensen S, Fog K, Pakkenberg B, Pedersen LØ. Autoimmune antibody decline in Parkinson's disease and multiple system atrophy; a step towards immunotherapeutic strategies. Mol Neurodegener. 2017;12:44. https://doi.org/10.1186/s13024-017-0187-7.
19. Folke J, Rydbirk R, Løkkegaard A, Hejl A-M, Winge K, Starhof C, Salvesen L, Pedersen LØ, Aznar S, Pakkenberg B, Brudek T. Cerebrospinal uid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord. 2021;87:98–104. https://doi.org/10.1016/j.parkreldis.2021.05.001.
20. Folke J, Bergholt E, Pakkenberg B, Aznar S, Brudek T. Alpha-synuclein autoimmune decline in Prodromal multiple system atrophy and Parkinson's Disease. Int J Mol Sci. 2022;23:6554. https://doi.org/10.3390/ijms23126554.
21. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum Anti-Aβ antibodies in Alzheimer Disease, Alzheimer dis. Assoc Disord 20 (2006). https://journals.lww.com/alzheimerjournal/Fulltext/2006/07000/Low_Avidity_and_Level_of_Serum_Anti_A__Antibodies.1.aspx
22. Folke J, Ferreira N, Brudek T, Borghammer P, Van Den Berge N. Passive Immunization in Alpha-Synuclein Preclinical Animal models. Biomolecules. 2022;12. https://doi.org/10.3390/biom12020168.
23. Sims JR, Zimmer JA, Evans CD, Lu M, Arday o P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM. 2 investigators, Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512–27. https://doi.org/10.1001/jama.2023.13239.
24. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ proto bril antibody. Alzheimers Res Ther. 2021;13:80. https://doi.org/10.1186/s13195-021-00813-8.
25. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30:1591–601. https://doi.org/10.1002/mds.26424.
26. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–6. https://doi.org/10.1212/01.wnl.0000324625.00404.15.
27. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE,

El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Gra□-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100. https://doi.org/10.1212/WNL.0000000000004058.

28. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.
29. Folke J, Rydbirk R, Løkkegaard A, Salvesen L, Hejl A-M, Starhof C, Bech S, Winge K, Christensen S, Pedersen LØ, Aznar S, Pakkenberg B, Brudek T. Distinct autoimmune Anti-α-Synuclein antibody patterns in multiple system atrophy and Parkinson's Disease. Front Immunol. 2019;10:2253. https://doi.org/10.3389/□mmu.2019.02253.
30. Fox J, Weisberg S. An R companion to Applied Regression, Second Edi. SAGE; 2011.
31. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008;50:346–63. https://doi.org/10.1002/bimj.200810425.
32. Wei T, Simko V. R package corrplot: visualization of a correlation matrix, (2017). https://github.com/taiyun/corrplot
33. Team RC. R: A Language and Environment for Statistical Computing, (2014).
34. Nielsen AK, Folke J, Owczarek S, Svenstrup K, Winge K, Pakkenberg B, Aznar S, Brudek T. TDP-43 speci□c autoantibody decline in amyotrophic lateral sclerosis: implications for immunotherapeutic strategies, Neurol. Neuroimmunol. Neuroin□ammation In; 2020.
35. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57:801–5. https://doi.org/10.1212/wnl.57.5.801.
36. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67:1605–11. https://doi.org/10.1212/01.wnl.0000242630.52203.8f.
37. Lashley T, Holton JL, Gray E, Kirkham K, O'Sullivan SS, Hilbig A, Wood NW, Lees AJ, Revesz T. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008;115:417–25. https://doi.org/10.1007/s00401-007-0336-0.
38. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci o□ J Soc Neurosci. 2010;30:7281–9. https://doi.org/10.1523/JNEUROSCI.0490-10.2010.
39. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66–79. https://doi.org/10.1016/j.neuron.2009.12.023.
40. Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179:954–63. https://doi.org/10.1016/j.ajpath.2011.04.013.
41. Alam MM, Yang D, Li X-Q, Liu J, Back TC, Trivett A, Karim B, Barbut D, Zaslo□ M, Oppenheim JJ. Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function. Cell Rep. 2022;38:110090. https://doi.org/10.1016/j.celrep.2021.110090.
42. Lutz HU. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun. 2007;29:287–94. https://doi.org/10.1016/j.jaut.2007.07.007.
43. Scott KM, Kouli A, Yeoh SL, Clatworthy MR, Williams-Gray CH. A systematic review and Meta-analysis of alpha synuclein auto-antibodies in Parkinson's Disease. Front Neurol. 2018;9:815. https://doi.org/10.3389/fneur.2018.00815.
44. Lundbeck AS, Lundbeck H. A/S: Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders - Inderes, (2024) 1–3. https://www.inderes.dk/en/releases/h-lundbeck-as-lundbeck-presents-encouraging-results-from-the-lu-af82422-trial-for-multiple-system-atrophy-at-the-international-adpd-2024-conference-on-neurodegenerative-disorders
45. Horvath I, Iashchishyn IA, Forsgren L, Morozova-Roche LA. Immunochemical detection of α-Synuclein autoantibodies in Parkinson's Disease: correlation between plasma and cerebrospinal □uid levels. ACS Chem Neurosci. 2017;8:1170–6. https://doi.org/10.1021/acschemneuro.7b00063.
46. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal □uid of Lewy body-associated dementias. J Alzheimers Dis. 2011;26:171–9. https://doi.org/10.3233/JAD-2011-110221.
47. Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, Kolassa I-T, Przybylski M, Manea M, von Arnim CAF. Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal □uid of Alzheimer's disease patients. PLoS ONE. 2013;8:e68996. https://doi.org/10.1371/journal.pone.0068996.
48. Liu Y-H, Wang J, Li Q-X, Fowler CJ, Zeng F, Deng J, Xu Z-Q, Zhou H-D, Doecke JD, Villemagne VL, Lim YY, Masters CL, Wang Y-J. Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. Sci Adv. 2021;7. https://doi.org/10.1126/sciadv.abb0457.
49. Scott KM, Chong YT, Park S, Wijeyekoon RS, Hayat S, Mathews RJ, Fitzpatrick Z, Tyers P, Wright G, Whitby J, Barker RA, Hu MT, Williams-Gray CH, Clatworthy MR. B lymphocyte responses in Parkinson's disease and their possible signi□cance in disease progression. Brain Commun. 2023;5:fcad060. https://doi.org/10.1093/braincomms/fcad060.
50. Kim K, Wang X, Ragonnaud E, Bodogai M, Illouz T, DeLuca M, McDevitt RA, Gusev F, Okun E, Rogaev E, Biragyn A. Therapeutic B-cell depletion reverses progression of Alzheimer's disease. Nat Commun. 2021;12:2185. https://doi.org/10.1038/s41467-021-22479-4.
51. Grönwall C, Vas J, Silverman GJ. Protective roles of natural IgM antibodies. Front Immunol. 2012;3:1–10. https://doi.org/10.3389/□mmu.2012.00066.
52. Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, function, and therapeutic use of IgM antibodies. Antibodies (Basel Switzerland). 2020;9. https://doi.org/10.3390/antib9040053.
53. Jones K, Savulescu AF, Brombacher F, Hadebe S, Immunoglobulin M. Health and diseases: how far have we come and what Next? Front Immunol. 2020;11:595535. https://doi.org/10.3389/□mmu.2020.595535.
54. Albus A, Kronimus Y, Neumann S, Vidovic N, Frenzel A, Kuhn P, Seifert M, Ziehm T, van der Wurp H, Dodel R. E□ects of a Multimerized recombinant autoantibody against Amyloid-β. Neuroscience. 2021;463:355–69. https://doi.org/10.1016/j.neuroscience.2021.03.006.
55. Ehrenstein MR, Cook HT, Neuberger MS. De□ciency in serum immunoglobulin (ig)m predisposes to Development of Igg autoantibodies. J Exp Med. 2000;191:1253–8. https://doi.org/10.1084/jem.191.7.1253.
56. Li Y, Jin L, Chen T. The e□ects of secretory IgA in the Mucosal Immune System. Biomed Res Int. 2020;2020:2032057. https://doi.org/10.1155/2020/2032057.
57. Pabst O, Slack E. IgA and the intestinal microbiota: the importance of being speci□c. Mucosal Immunol. 2020;13:12–21. https://doi.org/10.1038/s41385-019-0227-4.
58. Shi J, Wang Y, Chen D, Xu X, Li W, Li K, He J, Su W, Luo Q. The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease. Appl Microbiol Biotechnol. 2023;107:1917–29. https://doi.org/10.1007/s00253-023-12410-w.
59. Chandra R, Hiniker A, Kuo Y-M, Nussbaum RL, Liddle RA. α-Synuclein in gut endocrine cells and its implications for Parkinson's disease. JCI Insight. 2017;2. https://doi.org/10.1172/jci.insight.92295.
60. Çamcı G, Oğuz S. Association between Parkinson's Disease and Helicobacter Pylori. J Clin Neurol. 2016;12:147–50. https://doi.org/10.3988/jcn.2016.12.2.147.
61. Peelaerts W, Mercado G, George S, Villumsen M, Kasen A, Aguileta M, Linstow C, Sutter AB, Kuhn E, Stetzik L, Sheridan R, Bergkvist L, Meyerdirk L, Lindqvist A, Gavis MLE, Van den Haute C, Hultgren SJ, Baekelandt V, Pospisilik JA, Brudek T, Aznar S, Steiner JA, Henderson MX, Brundin L, Ivanova MI, Hannan TJ, Brundin P. Urinary tract infections trigger synucleinopathy via the innate immune response. Acta Neuropathol. 2023;145:541–59. https://doi.org/10.1007/s00401-023-02562-4.
62. Cheng Y, Tong Q, Yuan Y, Song X, Jiang W, Wang Y, Li W, Li Y, Zhang K. α-Synuclein induces prodromal symptoms of Parkinson's disease via activating TLR2/MyD88/NF-κB pathway in Schwann cells of vagus nerve in a rat model. J Neuroin□ammation. 2023;20:36. https://doi.org/10.1186/s12974-023-02720-1.
63. Kim S, Kwon S-H, Kam T-I, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS. Transneuronal Propagation of pathologic

α-Synuclein from the gut to the Brain models Parkinson's Disease. Neuron. 2019;103:627–e6417. https://doi.org/10.1016/j.neuron.2019.05.035.
64. Wang P, Luo M, Zhou W, Jin X, Xu Z, Yan S, Li Y, Xu C, Cheng R, Huang Y, Lin X, Yao L, Nie H, Jiang Q. Global characterization of Peripheral B cells in Parkinson's disease by single-cell RNA and BCR sequencing. Front Immunol. 2022;13. https://doi.org/10.3389/fmmu.2022.814239.
65. Fitzpatrick Z, Frazer G, Ferro A, Clare S, Bouladoux N, Ferdinand J, Tuong ZK, Negro-Demontel ML, Kumar N, Suchanek O, Tajsic T, Harcourt K, Scott K, Bashford-Rogers R, Helmy A, Reich DS, Belkaid Y, Lawley TD, McGavern DB, Clatworthy MR. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature. 2020;587:472–6. https://doi.org/10.1038/s41586-020-2886-4.
66. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. The Amyloid-β pathway in Alzheimer's Disease. Mol Psychiatry. 2021;26:5481–503. https://doi.org/10.1038/s41380-021-01249-0.
67. Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, Ma Y, Starke M, Ebentheuer J, Sixel-Döring F, Muntean M-L, Schade S, Trenkwalder C, Soto C, Mollenhauer B. Accurate detection of α-Synuclein seeds in cerebrospinal fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. Mov Disord. 2023;38:567–78. https://doi.org/10.1002/mds.29329.
68. Kluge A, Schaefer E, Bunk J, Sommerauer M, Röttgen S, Schulte C, Roeben B, von Thaler A-K, Welzel J, Lucius R, Heinzel S, Xiang W, Eschweiler GW, Maetzler W, Suenkel U, Berg D. Detecting misfolded α-Synuclein in blood years before the diagnosis of Parkinson's Disease. Mov Disord. 2024;39:1289–99. https://doi.org/10.1002/mds.29766.
69. Reyneveld GI, Savelkoul HFJ, Parmentier HK. Current understanding of natural antibodies and exploring the possibilities of Modulation using Veterinary models. Rev Front Immunol. 2020;11. https://doi.org/10.3389/fmmu.2020.02139.

Publisher's note